These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 11054443)

  • 1. Time to clinical response: an outcome of antibiotic therapy of febrile neutropenia with implications for quality and cost of care.
    Elting LS; Rubenstein EB; Rolston K; Cantor SB; Martin CG; Kurtin D; Rodriguez S; Lam T; Kanesan K; Bodey G
    J Clin Oncol; 2000 Nov; 18(21):3699-706. PubMed ID: 11054443
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current attitudes for therapy of febrile neutropenia with consideration to cost-effectiveness.
    Klastersky J
    Curr Opin Oncol; 1998 Jul; 10(4):284-90. PubMed ID: 9702394
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early hospital discharge versus continued hospitalization in febrile pediatric cancer patients with prolonged neutropenia: A randomized, prospective study.
    Ahmed N; El-Mahallawy HA; Ahmed IA; Nassif S; El-Beshlawy A; El-Haddad A
    Pediatr Blood Cancer; 2007 Nov; 49(6):786-92. PubMed ID: 17366527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacoeconomic analysis of empirical therapy with ceftazidime alone or combination antibiotics for febrile neutropenia in cancer patients.
    Dranitsaris G; Tran TM; McGeer A; Narine L
    Pharmacoeconomics; 1995 Jan; 7(1):49-62. PubMed ID: 10155293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized controlled trial comparing oral amoxicillin-clavulanate and ofloxacin with intravenous ceftriaxone and amikacin as outpatient therapy in pediatric low-risk febrile neutropenia.
    Gupta A; Swaroop C; Agarwala S; Pandey RM; Bakhshi S
    J Pediatr Hematol Oncol; 2009 Sep; 31(9):635-41. PubMed ID: 19684522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Meropenem versus ceftazidime in the treatment of cancer patients with febrile neutropenia: a randomized, double-blind trial.
    Feld R; DePauw B; Berman S; Keating A; Ho W
    J Clin Oncol; 2000 Nov; 18(21):3690-8. PubMed ID: 11054442
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Cost of antibiotic therapy in neutropenic patients undergoing peripheral blood stem cell transplantation for breast cancer].
    Palau J; Picón I; Aznar E; Climent MA; Máiquez J
    Rev Esp Quimioter; 2000 Jun; 13(2):193-8. PubMed ID: 10918094
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imipenem/cilastatin versus piperacillin/tazobactam plus amikacin for empirical therapy in febrile neutropenic patients: results of the COSTINE study.
    Sanz MA; Bermúdez A; Rovira M; Besalduch J; Pascual MJ; Nocea G; Sanz-Rodríguez C;
    Curr Med Res Opin; 2005 May; 21(5):645-55. PubMed ID: 15969864
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes and costs of febrile neutropenia: adventures in the science and art of treatment choices.
    Elting LS; Cantor SB
    Support Care Cancer; 2002 Apr; 10(3):189-96. PubMed ID: 11904783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of febrile neutropenic patients with cancer who require hospitalization: a prospective randomized study comparing imipenem and cefepime.
    Raad II; Escalante C; Hachem RY; Hanna HA; Husni R; Afif C; Boktour MR; Whimbey EE; Kontoyiannis D; Jacobson K; Kantarjian H; Levett LM; Rolston KV
    Cancer; 2003 Sep; 98(5):1039-47. PubMed ID: 12942573
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Criteria for response in patients in clinical trials of empiric antibiotic regimens for febrile neutropenia. Is there agreement?
    Feld R
    Support Care Cancer; 1998 Sep; 6(5):444-8. PubMed ID: 9773461
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Febrile neutropenia in paediatric peripheral blood stem cell transplantation, in -vitro sensitivity data and clinical response to empirical antibiotic therapy.
    Ansari SH; Nasim S; Ahmed A; Irfan M; Ishaque A; Farzana T; Panjwani VK; Taj M; Shamsi TS
    J Coll Physicians Surg Pak; 2006 Nov; 16(11):704-8. PubMed ID: 17052420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Isepamicin once daily plus ceftriaxone versus amikacin plus ceftriaxone in febrile neutropenic patients.
    Herbrecht R; Blaise D; Espinouse D; Leblond V; Sadoun A; Sauvage C; Cordonnier C; Minozzi C
    J Chemother; 1995 Jun; 7 Suppl 2():103-10. PubMed ID: 8622099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early hospital discharge followed by outpatient management versus continued hospitalization of children with cancer, fever, and neutropenia at low risk for invasive bacterial infection.
    Santolaya ME; Alvarez AM; Avilés CL; Becker A; Cofré J; Cumsille MA; O'Ryan ML; Payá E; Salgado C; Silva P; Tordecilla J; Varas M; Villarroel M; Viviani T; Zubieta M
    J Clin Oncol; 2004 Sep; 22(18):3784-9. PubMed ID: 15365075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Management of 315neutropenic febrile episodes in a cancer center].
    Dutronc H; Billhot M; Dupon M; Eghbali H; Donamaria C; Dauchy FA; Reiffers J
    Med Mal Infect; 2009 Jun; 39(6):388-93. PubMed ID: 19062208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Home antibiotic therapy for low-risk cancer patients with fever and neutropenia: a pilot study of 30 patients based on a validated prediction rule.
    Talcott JA; Whalen A; Clark J; Rieker PP; Finberg R
    J Clin Oncol; 1994 Jan; 12(1):107-14. PubMed ID: 8270967
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contemporary antimicrobial susceptibility patterns of bacterial pathogens commonly associated with febrile patients with neutropenia.
    Jones RN
    Clin Infect Dis; 1999 Sep; 29(3):495-502. PubMed ID: 10530435
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The cost-effectiveness of empirical antibiotic treatments for high-risk febrile neutropenic patients: A decision analytic model.
    Tori K; Tansarli GS; Parente DM; Kalligeros M; Ziakas PD; Mylonakis E
    Medicine (Baltimore); 2020 May; 99(20):e20022. PubMed ID: 32443305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A new ciprofloxacin stepdown program in the treatment of high-risk febrile neutropenia: a clinical and economic analysis.
    Marra CA; Frighetto L; Quaia CB; de Lemos ML; Warkentin DI; Marra F; Jewesson PJ
    Pharmacotherapy; 2000 Aug; 20(8):931-40. PubMed ID: 10939554
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk-adapted approach for fever and neutropenia in paediatric cancer patients--a national multicentre study.
    Miedema KG; Tissing WJ; Abbink FC; Ball LM; Michiels EM; van Vliet MJ; de Vries WY; Kamps WA; Norbruis OF; Fiocco M; de Groot-Kruseman HA; van de Wetering MD; de Bont ES
    Eur J Cancer; 2016 Jan; 53():16-24. PubMed ID: 26700076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.